Protein disulfide isomerase family 6 promotes the imatinib-resistance of renal cell carcinoma by regulation of Wnt3a-Frizzled1 axis

Yong Huang, Ping He, Juan DingBioengineered 2021 · DOI

TL;DR

This study identifies Protein Disulfide Isomerase Family 6 (PDIA6) as a key driver of imatinib resistance in renal cell carcinoma (RCC). By downregulating PDIA6, researchers sensitized resistant RCC cells to imatinib, suppressed their proliferation, promoted apoptosis, and impaired DNA damage repair, offering a potential therapeutic target for overcoming treatment resistance.

What Problem Does This Paper Address?

Renal cell carcinoma (RCC) is a significant cause of cancer-related deaths, and while imatinib offers a targeted therapy for advanced cases, a substantial challenge is the development of resistance to this drug. This resistance significantly limits treatment efficacy and necessitates the exploration of novel therapeutic strategies. The paper addresses the critical need to understand the molecular mechanisms underlying imatinib resistance in RCC and to identify potential targets for overcoming it. While PDIA6 has been implicated in chemoresistance in other cancers, its specific role in imatinib-resistant RCC was previously uncharacterized.

Methods

The researchers employed a multi-pronged approach to investigate PDIA6's role:

  • Tissue and Cell Analysis: They compared PDIA6 expression levels in imatinib-resistant and sensitive RCC tissues and cell lines using quantitative reverse transcription PCR (qRT-PCR) and Western blotting.
  • In Vitro Resistance Model: An imatinib-resistant RCC cell line (A498/R) was established by prolonged exposure of A498 cells to increasing concentrations of imatinib.
  • Gene Silencing: Small hairpin RNA (shRNA) was used to specifically knock down PDIA6 expression in A498/R cells.
  • Functional Assays:
    • Cell Viability and Proliferation: Cell Counting Kit-8 (CCK8) assays and crystal violet staining were used to assess cell viability and proliferation rates. The half-maximal inhibitory concentration (IC50) of imatinib was determined to quantify drug sensitivity.
  • Apoptosis Assays: Flow cytometry (Annexin V-FITC/PI staining) and Western blotting for apoptosis-related proteins (Bcl-2, Bax, cleaved caspase-3) were performed.
  • DNA Damage Repair Assays: Immunofluorescence for γH2AX (a marker of DNA double-strand breaks) and Western blotting for DNA damage repair proteins (p-DNA-PK, Rad51) were conducted.
  • Pathway Analysis: Western blotting was used to assess the expression of key proteins in the Wnt3a-Frizzled1 (Wnt3a-FZD1) signaling pathway.
  • Rescue Experiments: Overexpression of Frizzled1 (FZD1) was performed in PDIA6-silenced cells to determine if restoring FZD1 could reverse the observed effects.

Datasets

The study utilized:

  • Human Renal Cell Carcinoma Tissues: Samples were collected from 60 patients (24 imatinib-resistant, 36 imatinib-sensitive) treated at the Hospital of Chengdu University of Traditional Chinese Medicine.
  • Renal Cell Carcinoma Cell Lines: The A498 cell line was used as the parental line, and an imatinib-resistant derivative (A498/R) was generated in-house.

Key Insights and Ideas

  • PDIA6 as a Resistance Driver: The most significant insight is the direct link established between elevated PDIA6 expression and imatinib resistance in RCC. This suggests PDIA6 isn't just a bystander but an active contributor to the resistant phenotype.
  • Multifaceted Role of PDIA6: PDIA6 doesn't just confer resistance; it actively promotes cell proliferation, suppresses apoptosis, and enhances DNA damage repair mechanisms in resistant cells. This comprehensive impact highlights its central role in maintaining the resistant state.
  • Wnt3a-FZD1 Axis as a Key Mediator: The study elegantly connects PDIA6 to the Wnt3a-FZD1 signaling pathway. The downregulation of Wnt3a and FZD1 upon PDIA6 silencing suggests that PDIA6 might be activating this pathway, which in turn drives resistance. This provides a mechanistic link for PDIA6's effects.
  • Therapeutic Potential of PDIA6 Inhibition: The successful sensitization of resistant cells to imatinib upon PDIA6 knockdown strongly suggests that targeting PDIA6 could be a viable strategy to re-sensitize patients who have developed resistance.

Key Results

  • PDIA6 Upregulation: PDIA6 mRNA and protein levels were significantly higher in imatinib-resistant RCC tissues and cell lines compared to their sensitive counterparts.
  • Sensitization to Imatinib: Knockdown of PDIA6 in A498/R cells decreased the IC50 of imatinib from 15.04 µM to 4.67 µM, indicating a substantial increase in sensitivity.
  • Suppressed Proliferation and Enhanced Apoptosis: PDIA6 silencing reduced cell proliferation and increased apoptosis in A498/R cells, evidenced by decreased Bcl-2 and increased Bax and cleaved caspase-3 levels.
  • Impaired DNA Damage Repair: Knockdown of PDIA6 led to increased γH2AX immunofluorescence and reduced levels of p-DNA-PK and Rad51 in imatinib-treated A498/R cells, suggesting impaired DNA damage repair.
  • Wnt3a-FZD1 Pathway Inactivation: PDIA6 knockdown resulted in downregulated Wnt3a and FZD1 protein expression.
  • FZD1 Overexpression Reverses Effects: Overexpressing FZD1 in PDIA6-silenced cells partially reversed the increased apoptosis and decreased proliferation, further supporting the role of the Wnt3a-FZD1 axis.

Limitations and Future Work

  • In Vivo Validation: The study was primarily conducted using in vitro models. Future research should focus on validating these findings in animal models of imatinib-resistant RCC to assess the therapeutic efficacy and safety of PDIA6 inhibition in a more complex biological system.
  • Broader Patient Cohorts: While the study used patient tissues, expanding the analysis to larger and more diverse patient cohorts would strengthen the generalizability of the findings.
  • Specific PDIA6 Isoforms/Interactions: The paper focuses on PDIA6 as a whole. Further investigation into specific PDIA6 isoforms or its direct protein-protein interactions could reveal more nuanced mechanisms of resistance.
  • Clinical Translation: The ultimate goal would be to develop clinical trials investigating PDIA6 inhibitors, either alone or in combination with imatinib, for patients with resistant RCC.
  • Other Signaling Pathways: While the Wnt3a-FZD1 pathway was highlighted, PDIA6 might influence other pathways contributing to resistance. Further exploration of these could provide a more complete picture.

Summary updated

Abstract

Imatinib is a nontoxic tyrosine kinase inhibitor, used in the treatment of advanced renal cell carcinoma. However, some patients with renal cell carcinoma develop resistance to imatinib. Protein disulfide isomerase family 6 (PDIA6) was involved in the chemo-resistance of lung adenocarcinoma. In this study, the effect of PDIA6 on imatinib-resistance of renal cell carcinoma was investigated. First, PDIA6 was found to be up-regulated in the imatinib-resistant renal cell carcinoma tissues and cells. Functional assays showed that knockdown of PDIA6 sensitized imatinib-resistant renal cell carcinoma cells to imatinib through decreasing the half-maximal inhibitory concentration (IC50) of imatinib-resistant renal cell carcinoma cells. Secondly, cell proliferation of imatinib-resistant renal cell carcinoma cells was suppressed by PDIA6 silencing, and the apoptosis was promoted with reduced Bcl-2, enhanced Bax and cleaved caspase-3. Moreover, the interference of PDIA6 increased phosphorylation of H2A histone family member X (γH2AX), while decreased Rad51 and phosphorylated DNA-dependent protein kinase (DNA-PK) (p-DNA-PK) in imatinib-resistant renal cell carcinoma cells. Lastly, protein expression levels of Wnt3a and Frizzled1 (FZD1) in imatinib-resistant renal cell carcinoma cells were down-regulated by silencing of PDIA6. Over-expression of FZD1 attenuated PDIA6 silencing-induced increase in cell apoptosis and decrease in cell proliferation in imatinib-resistant renal cell carcinoma cells. In conclusion, knockdown of PDIA6 sensitized imatinib-resistant renal cell carcinoma cells into imatinib through inactivation of Wnt3a-FZD1 axis.
BibTeX
@inproceedings{huang2021protein,
  author = {Yong Huang and Ping He and Juan Ding},
  title = {{Protein disulfide isomerase family 6 promotes the imatinib-resistance of renal cell carcinoma by regulation of Wnt3a-Frizzled1 axis}},
  booktitle = {Bioengineered},
  year = {2021},
  doi = {10.1080/21655979.2021.2005218},
}
Figure